Further  ||| S:0 E:8 ||| JJ
strategies  ||| S:8 E:19 ||| NNS
for  ||| S:19 E:23 ||| IN
treating  ||| S:23 E:32 ||| VBG
fibromyalgia ||| S:32 E:44 ||| NNS
:  ||| S:44 E:46 ||| :
the  ||| S:46 E:50 ||| DT
role  ||| S:50 E:55 ||| NN
of  ||| S:55 E:58 ||| IN
serotonin  ||| S:58 E:68 ||| NN
and  ||| S:68 E:72 ||| CC
norepinephrine  ||| S:72 E:87 ||| FW
reuptake  ||| S:87 E:96 ||| FW
inhibitors  ||| S:96 E:107 ||| FW
Fibromyalgia  ||| S:107 E:120 ||| NNP
and  ||| S:120 E:124 ||| CC
associated  ||| S:124 E:135 ||| JJ
conditions  ||| S:135 E:146 ||| NNS
such  ||| S:146 E:151 ||| JJ
as  ||| S:151 E:154 ||| IN
irritable  ||| S:154 E:164 ||| JJ
bowel  ||| S:164 E:170 ||| JJ
syndrome  ||| S:170 E:179 ||| NN
and  ||| S:179 E:183 ||| CC
temporomandibular  ||| S:183 E:201 ||| JJ
disorder  ||| S:201 E:210 ||| NNS
involve  ||| S:210 E:218 ||| VBP
dysfunctions  ||| S:218 E:231 ||| VBN
in  ||| S:231 E:234 ||| IN
central  ||| S:234 E:242 ||| JJ
sensitization  ||| S:242 E:256 ||| NN
and  ||| S:256 E:260 ||| CC
pain  ||| S:260 E:265 ||| NN
modulation ||| S:265 E:275 ||| NN
.  ||| S:275 E:277 ||| .
Central  ||| S:277 E:285 ||| JJ
nervous  ||| S:285 E:293 ||| JJ
system  ||| S:293 E:300 ||| NN
dysfunction  ||| S:300 E:312 ||| NNS
may  ||| S:312 E:316 ||| MD
also  ||| S:316 E:321 ||| RB
contribute  ||| S:321 E:332 ||| VB
to  ||| S:332 E:335 ||| TO
other  ||| S:335 E:341 ||| JJ
symptoms  ||| S:341 E:350 ||| NNS
characteristic  ||| S:350 E:365 ||| NN
of  ||| S:365 E:368 ||| IN
fibromyalgia ||| S:368 E:380 ||| NN
,  ||| S:380 E:382 ||| ,
such  ||| S:382 E:387 ||| JJ
as  ||| S:387 E:390 ||| IN
fatigue  ||| S:390 E:398 ||| NN
and  ||| S:398 E:402 ||| CC
sleep  ||| S:402 E:408 ||| JJ
disturbance ||| S:408 E:419 ||| NN
.  ||| S:419 E:421 ||| .
Two  ||| S:421 E:425 ||| CD
key  ||| S:425 E:429 ||| JJ
neurotransmitters  ||| S:429 E:447 ||| NN
in  ||| S:447 E:450 ||| IN
the  ||| S:450 E:454 ||| DT
pain  ||| S:454 E:459 ||| NN
modulation  ||| S:459 E:470 ||| NN
pathway  ||| S:470 E:478 ||| NNS
are  ||| S:478 E:482 ||| VBP
serotonin  ||| S:482 E:492 ||| VBN
and  ||| S:492 E:496 ||| CC
norepinephrine ||| S:496 E:510 ||| NN
.  ||| S:510 E:512 ||| .
Preclinical  ||| S:512 E:524 ||| JJ
studies  ||| S:524 E:532 ||| NNS
using  ||| S:532 E:538 ||| VBG
animal  ||| S:538 E:545 ||| JJ
models  ||| S:545 E:552 ||| NNS
of  ||| S:552 E:555 ||| IN
chronic  ||| S:555 E:563 ||| JJ
pain  ||| S:563 E:568 ||| NN
have  ||| S:568 E:573 ||| VBP
shown  ||| S:573 E:579 ||| VBN
that  ||| S:579 E:584 ||| IN
pharmacologic  ||| S:584 E:598 ||| JJ
agents  ||| S:598 E:605 ||| NNS
that  ||| S:605 E:610 ||| IN
combine  ||| S:610 E:618 ||| JJ
serotonergic  ||| S:618 E:631 ||| NN
and  ||| S:631 E:635 ||| CC
noradrenergic  ||| S:635 E:649 ||| JJ
reuptake  ||| S:649 E:658 ||| JJ
inhibition ||| S:658 E:668 ||| NN
,  ||| S:668 E:670 ||| ,
thus  ||| S:670 E:675 ||| RB
augmenting  ||| S:675 E:686 ||| VB
the  ||| S:686 E:690 ||| DT
function  ||| S:690 E:699 ||| NN
of  ||| S:699 E:702 ||| IN
these  ||| S:702 E:708 ||| DT
neurotransmitters ||| S:708 E:725 ||| NN
,  ||| S:725 E:727 ||| ,
have  ||| S:727 E:732 ||| VBP
stronger  ||| S:732 E:741 ||| JJR
analgesic  ||| S:741 E:751 ||| JJ
effects  ||| S:751 E:759 ||| NNS
than  ||| S:759 E:764 ||| IN
agents  ||| S:764 E:771 ||| NNS
that  ||| S:771 E:776 ||| WDT
inhibit  ||| S:776 E:784 ||| VBP
reuptake  ||| S:784 E:793 ||| VBN
of  ||| S:793 E:796 ||| IN
either  ||| S:796 E:803 ||| DT
neurotransmitter  ||| S:803 E:820 ||| NN
alone ||| S:820 E:825 ||| RB
.  ||| S:825 E:827 ||| .
Although  ||| S:827 E:836 ||| IN
tricyclic  ||| S:836 E:846 ||| JJ
antidepressants  ||| S:846 E:862 ||| NNS
( ||| S:862 E:863 ||| -LRB-
TCAs ||| S:863 E:867 ||| NNP
)  ||| S:867 E:869 ||| -RRB-
inhibit  ||| S:869 E:877 ||| VBP
reuptake  ||| S:877 E:886 ||| VBN
of  ||| S:886 E:889 ||| IN
both  ||| S:889 E:894 ||| DT
serotonin  ||| S:894 E:904 ||| NN
and  ||| S:904 E:908 ||| CC
norepinephrine  ||| S:908 E:923 ||| NNS
and  ||| S:923 E:927 ||| CC
have  ||| S:927 E:932 ||| VBP
shown  ||| S:932 E:938 ||| VBN
efficacy  ||| S:938 E:947 ||| VBN
for  ||| S:947 E:951 ||| IN
the  ||| S:951 E:955 ||| DT
treatment  ||| S:955 E:965 ||| NN
of  ||| S:965 E:968 ||| IN
fibromyalgia ||| S:968 E:980 ||| NN
,  ||| S:980 E:982 ||| ,
long-term  ||| S:982 E:992 ||| JJ
use  ||| S:992 E:996 ||| NN
of  ||| S:996 E:999 ||| IN
these  ||| S:999 E:1005 ||| DT
drugs  ||| S:1005 E:1011 ||| NNS
is  ||| S:1011 E:1014 ||| VBZ
limited  ||| S:1014 E:1022 ||| VBN
owing  ||| S:1022 E:1028 ||| VBG
to  ||| S:1028 E:1031 ||| TO
poor  ||| S:1031 E:1036 ||| JJ
tolerability ||| S:1036 E:1048 ||| NN
.  ||| S:1048 E:1050 ||| .
Unlike  ||| S:1050 E:1057 ||| IN
TCAs ||| S:1057 E:1061 ||| NNP
,  ||| S:1061 E:1063 ||| ,
the  ||| S:1063 E:1067 ||| DT
newer  ||| S:1067 E:1073 ||| JJR
dual  ||| S:1073 E:1078 ||| JJ
reuptake  ||| S:1078 E:1087 ||| JJ
inhibitors  ||| S:1087 E:1098 ||| NN
of  ||| S:1098 E:1101 ||| IN
serotonin  ||| S:1101 E:1111 ||| NN
and  ||| S:1111 E:1115 ||| CC
norepinephrine ||| S:1115 E:1129 ||| NN
,  ||| S:1129 E:1131 ||| ,
such  ||| S:1131 E:1136 ||| JJ
as  ||| S:1136 E:1139 ||| IN
the  ||| S:1139 E:1143 ||| DT
drugs  ||| S:1143 E:1149 ||| NNS
approved  ||| S:1149 E:1158 ||| VBN
by  ||| S:1158 E:1161 ||| IN
the  ||| S:1161 E:1165 ||| DT
US  ||| S:1165 E:1168 ||| NNP
Food  ||| S:1168 E:1173 ||| NNP
and  ||| S:1173 E:1177 ||| CC
Drug  ||| S:1177 E:1182 ||| NNP
Administration  ||| S:1182 E:1197 ||| NNP
( ||| S:1197 E:1198 ||| -LRB-
FDA ||| S:1198 E:1201 ||| NNP
)  ||| S:1201 E:1203 ||| -RRB-
for  ||| S:1203 E:1207 ||| IN
fibromyalgia ||| S:1207 E:1219 ||| NN
,  ||| S:1219 E:1221 ||| ,
milnacipran  ||| S:1221 E:1233 ||| NN
and  ||| S:1233 E:1237 ||| CC
duloxetine ||| S:1237 E:1247 ||| NN
,  ||| S:1247 E:1249 ||| ,
do  ||| S:1249 E:1252 ||| VBP
not  ||| S:1252 E:1256 ||| RB
possess  ||| S:1256 E:1264 ||| VB
significant  ||| S:1264 E:1276 ||| JJ
affinity  ||| S:1276 E:1285 ||| NN
for  ||| S:1285 E:1289 ||| IN
other  ||| S:1289 E:1295 ||| JJ
neurotransmitter  ||| S:1295 E:1312 ||| JJ
systems ||| S:1312 E:1319 ||| NNS
,  ||| S:1319 E:1321 ||| ,
resulting  ||| S:1321 E:1331 ||| VBG
in  ||| S:1331 E:1334 ||| IN
diminished  ||| S:1334 E:1345 ||| JJ
side  ||| S:1345 E:1350 ||| NN
effects  ||| S:1350 E:1358 ||| NNS
and  ||| S:1358 E:1362 ||| CC
enhanced  ||| S:1362 E:1371 ||| JJ
tolerability ||| S:1371 E:1383 ||| NN
.  ||| S:1383 E:1385 ||| .
Both  ||| S:1385 E:1390 ||| DT
duloxetine  ||| S:1390 E:1401 ||| NN
and  ||| S:1401 E:1405 ||| CC
milnacipran  ||| S:1405 E:1417 ||| NNS
have  ||| S:1417 E:1422 ||| VBP
shown  ||| S:1422 E:1428 ||| VBN
efficacy  ||| S:1428 E:1437 ||| VBN
in  ||| S:1437 E:1440 ||| IN
clinical  ||| S:1440 E:1449 ||| JJ
trials  ||| S:1449 E:1456 ||| NNS
by  ||| S:1456 E:1459 ||| IN
improving  ||| S:1459 E:1469 ||| VBG
pain  ||| S:1469 E:1474 ||| NN
and  ||| S:1474 E:1478 ||| CC
other  ||| S:1478 E:1484 ||| JJ
symptoms  ||| S:1484 E:1493 ||| NNS
associated  ||| S:1493 E:1504 ||| VBN
with  ||| S:1504 E:1509 ||| IN
fibromyalgia ||| S:1509 E:1521 ||| NN
.  ||| S:1521 E:1523 ||| .
Both  ||| S:1523 E:1528 ||| DT
compounds  ||| S:1528 E:1538 ||| NNS
inhibit  ||| S:1538 E:1546 ||| VBP
the  ||| S:1546 E:1550 ||| DT
serotonin  ||| S:1550 E:1560 ||| NN
and  ||| S:1560 E:1564 ||| CC
norepinephrine  ||| S:1564 E:1579 ||| JJ
transporters ||| S:1579 E:1591 ||| NN
;  ||| S:1591 E:1593 ||| :
however ||| S:1593 E:1600 ||| RB
,  ||| S:1600 E:1602 ||| ,
there  ||| S:1602 E:1608 ||| EX
is  ||| S:1608 E:1611 ||| VBZ
a  ||| S:1611 E:1613 ||| DT
difference  ||| S:1613 E:1624 ||| NN
in  ||| S:1624 E:1627 ||| IN
their  ||| S:1627 E:1633 ||| PRP$
affinities  ||| S:1633 E:1644 ||| NNS
and  ||| S:1644 E:1648 ||| CC
selectivity  ||| S:1648 E:1660 ||| NN
for  ||| S:1660 E:1664 ||| IN
these  ||| S:1664 E:1670 ||| DT
transporters ||| S:1670 E:1682 ||| NN
.  ||| S:1682 E:1684 ||| .
Although  ||| S:1684 E:1693 ||| IN
duloxetine  ||| S:1693 E:1704 ||| NN
has  ||| S:1704 E:1708 ||| VBZ
affinity  ||| S:1708 E:1717 ||| VBN
for  ||| S:1717 E:1721 ||| IN
both  ||| S:1721 E:1726 ||| DT
receptors ||| S:1726 E:1735 ||| NN
,  ||| S:1735 E:1737 ||| ,
it  ||| S:1737 E:1740 ||| PRP
is  ||| S:1740 E:1743 ||| VBZ
somewhat  ||| S:1743 E:1752 ||| RB
more  ||| S:1752 E:1757 ||| RBR
selective  ||| S:1757 E:1767 ||| JJ
for  ||| S:1767 E:1771 ||| IN
the  ||| S:1771 E:1775 ||| DT
serotonin  ||| S:1775 E:1785 ||| JJ
transporter ||| S:1785 E:1796 ||| NN
.  ||| S:1796 E:1798 ||| .
In  ||| S:1798 E:1801 ||| IN
contrast ||| S:1801 E:1809 ||| NN
,  ||| S:1809 E:1811 ||| ,
milnacipran  ||| S:1811 E:1823 ||| NN
is  ||| S:1823 E:1826 ||| VBZ
somewhat  ||| S:1826 E:1835 ||| RB
more  ||| S:1835 E:1840 ||| RBR
selective  ||| S:1840 E:1850 ||| JJ
for  ||| S:1850 E:1854 ||| IN
norepinephrine  ||| S:1854 E:1869 ||| NN
than  ||| S:1869 E:1874 ||| IN
serotonin  ||| S:1874 E:1884 ||| JJ
reuptake  ||| S:1884 E:1893 ||| JJ
inhibition ||| S:1893 E:1903 ||| NN
.  ||| S:1903 E:1905 ||| .
Pharmacologic  ||| S:1905 E:1919 ||| JJ
agents  ||| S:1919 E:1926 ||| NNS
that  ||| S:1926 E:1931 ||| WDT
specifically  ||| S:1931 E:1944 ||| RB
target  ||| S:1944 E:1951 ||| VB
serotonin  ||| S:1951 E:1961 ||| NNS
and  ||| S:1961 E:1965 ||| CC
norepinephrine  ||| S:1965 E:1980 ||| JJ
reuptake  ||| S:1980 E:1989 ||| NN
may  ||| S:1989 E:1993 ||| MD
prove  ||| S:1993 E:1999 ||| VB
to  ||| S:1999 E:2002 ||| TO
be  ||| S:2002 E:2005 ||| VB
valuable  ||| S:2005 E:2014 ||| JJ
tools  ||| S:2014 E:2020 ||| NNS
in  ||| S:2020 E:2023 ||| IN
the  ||| S:2023 E:2027 ||| DT
treatment  ||| S:2027 E:2037 ||| NN
of  ||| S:2037 E:2040 ||| IN
fibromyalgia ||| S:2040 E:2052 ||| NN
.  ||| S:2052 E:2054 ||| .
